학술논문
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study
Document Type
Article
Author
Montesinos, P.; Roboz, G.J.; Bulabois, C.-E.; Subklewe, M.; Platzbecker, U.; Ofran, Y.; Papayannidis, C.; Wierzbowska, A.; Shin, H.J.; Doronin, V.; Deneberg, S.; Yeh, S.-P.; Ozcan, M.A.; Knapper, S.; Cortes, J.; Pollyea, D.A.; Ossenkoppele, G.; Giralt, S.; Döhner, H.; Heuser, M.; Xiu, L.; Singh, I.; Huang, F.; Larsen, J.S.; Wei, A.H.
Source
In: Leukemia . (Leukemia, January 2021, 35(1):62-74)
Subject
Language
English
ISSN
14765551
08876924
08876924